RAP 0.00% 20.5¢ resapp health limited

Ann: Positive Results for Australian Prospective Paediatric Study, page-305

  1. 1,809 Posts.
    lightbulb Created with Sketch. 150
    You might be onto something if the app was being pitched at a hospital or GP setting in suburban Australia.

    However a hospital, an X-ray & a full clinical diagnosis for common resp. conditions (which requires access to the full range of diagnostic tools) by a doctor is not currently available globally to/or deemed necessary by many countries for all patients. That's where remote clinics, nurse practitioners & Telehealth fits in.
    RAP is initially taking ResApp (if fully validated & approved) to the European tele-health market which is much more evolved than it is Australia & on a steep growth curve. Beyond that (IMHO) there are broad applications for app inc. ED's, screening (pre-employment, airports) remote medicine and primary health care settings (home & community) just to name a few.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.